Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of “Moderate Buy” by Analysts

Compass Therapeutics, Inc. (NASDAQ:CMPX) has received a consensus recommendation of “Moderate Buy” from the fifteen brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, twelve have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $12.25.

Several brokerages have commented on CMPX. LADENBURG THALM/SH SH initiated coverage on shares of Compass Therapeutics in a research report on Wednesday, July 1st. They issued a “buy” rating and a $5.00 price objective on the stock. Citigroup restated a “market outperform” rating on shares of Compass Therapeutics in a research note on Thursday, June 4th. Guggenheim reaffirmed a “buy” rating and issued a $12.00 price target on shares of Compass Therapeutics in a report on Tuesday, March 24th. Canaccord Genuity Group dropped their price objective on Compass Therapeutics from $13.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, April 28th. Finally, Citizens Jmp reissued a “market outperform” rating and set a $10.00 price objective on shares of Compass Therapeutics in a report on Tuesday, April 28th.

Compass Therapeutics Price Performance

Shares of Compass Therapeutics stock opened at $2.02 on Tuesday. The firm has a market cap of $363.78 million, a PE ratio of -4.93 and a beta of 0.90. Compass Therapeutics has a 1 year low of $1.61 and a 1 year high of $6.88. The stock has a fifty day moving average price of $2.10 and a 200-day moving average price of $4.19.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.10). As a group, equities analysts anticipate that Compass Therapeutics will post -0.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CMPX. Strs Ohio purchased a new stake in Compass Therapeutics in the 1st quarter worth about $34,000. Creative Planning purchased a new stake in Compass Therapeutics during the second quarter valued at about $30,000. XTX Topco Ltd purchased a new stake in Compass Therapeutics during the second quarter valued at about $84,000. Invesco Ltd. lifted its holdings in Compass Therapeutics by 58.1% during the second quarter. Invesco Ltd. now owns 58,735 shares of the company’s stock valued at $153,000 after purchasing an additional 21,578 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its position in Compass Therapeutics by 11.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock worth $11,505,000 after purchasing an additional 449,868 shares during the period. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.